empulse-trial-benefit-acute-heart-failure empulse-trial-benefit-acute-heart-failure Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
emperor-reduced-chmp-positive-opinion emperor-reduced-chmp-positive-opinion CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
preserved-heart-failure-treatment-FDA-US-approval preserved-heart-failure-treatment-FDA-US-approval US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
emperor-preserved-heart-failure-toplineresults emperor-preserved-heart-failure-toplineresults Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
FDA-Fast-Track-chronic-kidney-disease FDA-Fast-Track-chronic-kidney-disease FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved FDA- HFpEF-breakthrough-designation-EMPEROR-preserved U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP
Partnering in Cardiometabolic Diseases MAY 2023 Corp Partnering in Cardiometabolic Diseases MAY 2023 Corp
Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf
Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
emperor-preserved-heart-failure-full-data emperor-preserved-heart-failure-full-data Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Survodutide Phase III study weight loss Survodutide Phase III study weight loss Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
biopharmaceuticals-in-china biopharmaceuticals-in-china Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.